Mukvych V. V., Severynovska O. V.

CAFFEINE EFFECT ON ECHOCARDIOGRAPHY PARAMETERS IN RATS WITH DOXORUBICIN-INDUCED CARDIOMYOPATHYS

---

Show/Download

About the author:

Mukvych V. V., Severynovska O. V.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Cancer remains one of the leading causes of death worldwide and in Ukraine, second only to cardiovascular disease. By 2025, the number of new cases of cancer may increase by 77%, translating to over 35 million diagnosed cases per year. Doxorubicin is a key chemotherapeutic agent used to treat various types of cancer. Its mechanism of action involves intercalating into DNA, inhibiting topoisomerase II, and inducing oxidative stress in tumor cells. However, one of the most promising areas of research is the study of the caffeine effect on the cardiovascular system in the context of doxorubicin-induced cardiomyopathy (DICM). The aim of the study is to investigate the caffeine effect on echocardiographic parameters in an experimental model of doxorubicin-induced cardiomyopathy in female rats to explore its potential cardioprotective effect and its role in regulating the autonomic nervous system. The study involved 36 white sexually mature female rats, which were randomly divided into three groups (12 animals per group): Group I – control group of female rats receiving saline (1 mg/kg) via gastric gavage, Group II – group of female rats treated with 1 mg/kg of doxorubicin via gastric gavage, Group III – group of female rats treated with caffeine (25mg/kg per day) and doxorubicin (1 mg/kg) administered intragastrically. Echocardiography was performed using the MyLab Gamma ultrasound system by Esaote with a linear transducer (SL 3235). The results indicate that doxorubicin causes the DICM development, while caffeine exerts a pronounced cardioprotective effect, preventing the deterioration of heart function. These findings may be of significant value for future studies exploring the use of caffeine and its derivatives for myocardial protection during doxorubicin-based chemotherapy.

Tags:

Bibliography:

1. Li Q, Xia С, Li Н, Yan Х, Yang F, Cao M, et al. Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics. Front Med. 2024;18(5):911-20. DOI: 10.1007/s11684-024-1058-6.
2.  Mukvych V, Severynovska O. Modulatory effect of caffeine on heart rate variability parameters in rats with doxorubicin-induced cardiomyopathy. Bulletin of Problems in Biology and Medicine. 2024;4(175):433-41. DOI: 10.29254/2077-4214-2024-4-175-433-441.
3. Prathumsap N, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies. Eur J Pharmacol. 2020;866:172818. DOI: 10.1016/j.ejphar.2019.172818.
4. Renu K, Abilash VG, Pichiah TP, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy – an update. Eur J Pharmacol. 2018;818:241-53. DOI: 10.1016/j.ejphar.2017.10.043.
5. Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I, et al. Doxorubicin – an agent with multiple mechanisms of anticancer activity. Cells. 2023;12(4):659. DOI: 10.3390/cells12040659.
6. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104:971-77. DOI: 10.1136/heartjnl-2017-312103.
7.  Li Y, Yan J, Yang P. The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell death. Cell Stress Chaperones. 2024;29(5):666-80. DOI: 10.1016/j.cstres.2024.09.001.
8. Kitakata H, Endo J, Ikura H, Moriyama H, Shirakawa K, Katsumata Y, et al. Therapeutic Targets for DOX-Induced Cardiomyopathy: Role of Apoptosis vs. Ferroptosis. Int J Mol Sci. 2022;23(3):1414. DOI: 10.3390/ijms23031414.
9. Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. DOI: 10.1016/j.biopha.2021.111708.
10. Li D, Yang Y, Wang S, He X, Liu M, Bai B, et al. Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biol. 2021;46:102089. DOI: 10.1016/j.redox.2021.102089.
11. Song X, Singh M, Lee KE, Vinayagam R, Kang SG. Caffeine: A multifunctional efficacious molecule with diverse health implications and emerging delivery systems. Int J Mol Sci. 2024;25(22):12003. DOI: 10.3390/ijms252212003.
12. Saimaiti A, Zhou DD, Li J, Xiong RG, Gan RY, Huang SY, et al. Dietary sources, health benefits, and risks of caffeine. Crit Rev Food Sci Nutr. 2023;63(29):9648-66. DOI: 10.1080/10408398.2022.2074362.
13. Xue S, Chen H, Zhang J, Tian R, Xie C, Sun Q, et al. Qishen granule alleviates doxorubicin-induced cardiotoxicity by suppressing ferroptosis via nuclear erythroid factor 2-related factor 2 (Nrf2) pathway. Ethnopharmacol. 2024;335:118604. DOI: 10.1016/j.jep.2024.118604.
14. Chen Y, Shi S, Dai Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed Pharmacother. 2022;156:113903. DOI: 10.1016/j.biopha.2022.113903.
15. Zapadnjuk IP, Zapadnjuk EA, Zaharija EA. Laboratornye zhivotnye: razvedenie, soderzhanie, ispolzovanie v eksperimente. Kyyv: Vishha shkola; 1983. 383 s.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 1, 176, 251-260 pages, index UDC 615.24:612.172-074:616.127-092.9:599.323.4

DOI:

10.29254/2077-4214-2025-1-176-251-260